Description

CANDIFACE 100 MG (1X10)

Indications

CANDIFACE 100 MG is primarily indicated for the treatment of fungal infections caused by susceptible strains of fungi. It is commonly prescribed for conditions such as candidiasis, which affects mucosal surfaces, skin, and systemic infections. The active ingredient in CANDIFACE, fluconazole, is effective against various species of Candida, making it a valuable option for both superficial and invasive fungal infections. Additionally, CANDIFACE may be used as a prophylactic treatment in immunocompromised patients to prevent fungal infections.

Mechanism of Action

The active component of CANDIFACE, fluconazole, belongs to the class of antifungal agents known as triazoles. Fluconazole works by inhibiting the enzyme lanosterol 14α-demethylase, which is crucial in the biosynthesis of ergosterol, an essential component of fungal cell membranes. By disrupting the synthesis of ergosterol, fluconazole compromises the integrity of the fungal cell membrane, leading to cell lysis and death. This mechanism makes fluconazole effective against a wide range of fungi, particularly Candida species.

Pharmacological Properties

CANDIFACE exhibits favorable pharmacokinetic properties, including good oral bioavailability and extensive tissue distribution. After oral administration, fluconazole is rapidly absorbed, with peak plasma concentrations typically occurring within 1 to 2 hours. The drug has a long half-life, allowing for once-daily dosing in most cases. Fluconazole is primarily excreted unchanged in the urine, making it suitable for treating urinary tract infections caused by fungi. The drug demonstrates low protein binding, which contributes to its effective tissue penetration.

Contraindications

CANDIFACE is contraindicated in patients with a known hypersensitivity to fluconazole or any other component of the formulation. Additionally, it should not be used in patients who are concurrently taking certain medications that are known to interact adversely with fluconazole, such as terfenadine, astemizole, or cisapride, due to the risk of serious cardiac arrhythmias. Caution is also advised in patients with a history of liver disease, as fluconazole is metabolized in the liver.

Side Effects

Common side effects of CANDIFACE may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea. Other potential side effects can include headache, dizziness, and skin rashes. Rare but serious side effects may involve hepatotoxicity, which can manifest as elevated liver enzymes or jaundice, and severe allergic reactions. Patients should be monitored for any signs of adverse effects, especially during the first few weeks of treatment.

Dosage and Administration

The recommended dosage of CANDIFACE 100 MG varies depending on the type and severity of the fungal infection being treated. For most adult patients with candidiasis, the initial dose is typically 150 mg as a single dose, followed by 100 mg daily for at least two weeks. In cases of systemic infections, higher doses may be required, and treatment duration may extend for several weeks or months. It is essential to follow the prescribing physician’s instructions regarding dosage and duration of therapy. CANDIFACE can be taken with or without food, and patients are advised to swallow the tablet whole with water.

Interactions

CANDIFACE may interact with several medications, which can alter its effectiveness or increase the risk of side effects. Notable interactions include anticoagulants such as warfarin, where fluconazole may enhance the anticoagulant effect, necessitating closer monitoring of INR levels. Other drugs that may interact with fluconazole include certain anticonvulsants, theophylline, and some antiretroviral medications. Patients should inform their healthcare provider of all medications they are currently taking to avoid potential interactions.

Precautions

Before initiating treatment with CANDIFACE, healthcare providers should assess the patient’s medical history, particularly regarding liver function and any history of hypersensitivity reactions. Caution is warranted in patients with renal impairment, as dosage adjustments may be necessary. Pregnant and breastfeeding women should also consult their healthcare provider before using CANDIFACE, as fluconazole can cross the placenta and is excreted in breast milk. Regular liver function tests may be recommended during prolonged therapy to monitor for potential hepatotoxicity.

Clinical Studies

Numerous clinical studies have evaluated the efficacy and safety of fluconazole in various fungal infections. A pivotal study published in the Journal of Antimicrobial Chemotherapy demonstrated that fluconazole is highly effective in treating oropharyngeal candidiasis in HIV-infected patients. Another study in the New England Journal of Medicine showed that fluconazole significantly reduced the incidence of fungal infections in neutropenic patients receiving chemotherapy. These studies underscore the drug’s role as a first-line treatment option for various fungal infections.

Conclusion

CANDIFACE 100 MG is a well-established antifungal medication indicated for the treatment of various fungal infections, particularly those caused by Candida species. Its mechanism of action, pharmacological properties, and clinical efficacy make it a valuable tool in managing fungal diseases. However, like all medications, it must be used responsibly, with attention to contraindications, potential side effects, and drug interactions. Patients should always consult with their healthcare provider to ensure safe and effective use of CANDIFACE.